Cara Therapeutics Inc

NASDAQ:CARAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Contact Information

Headquarters

400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901

Phone

203-406-3700

Fax

203-567-1510

Executives

Independent Chairman of the Board

Martin Vogelbaum

President, Chief Executive Officer, Director

Christopher Posner

Chief Financial Officer

Ryan Maynard

Senior Vice President - Research and Development, Chief Scientific Officer

Frederique Menzaghi

Chief Compliance Officer, General Counsel, Secretary

Scott Terrillion